21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should be covered by public plans – reveals a total of 1896 conflicts of interest.

CADTH is a not-for-profit organisation that provides health-care decision-makers with evidence and recommendations for optimal use of health technologies.

It has two arms that evaluate drugs and make recommendations to public drug plans about whether they should pay for the drugs for particular uses — one for cancer and one that looks at all other drugs. Both allow patient advocacy groups to make submissions about whether a drug should be funded, and in those submissions they must declare any donations from drug companies.

SPOILER ALERT - This article has been written by a long-term critic of the pharmaceutical industry.

Read The Conversation article